Related references
Note: Only part of the references are listed.Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
Lawrence R. Dick et al.
DRUG DISCOVERY TODAY (2010)
From Pathogenesis to Prevention of Castration Resistant Prostate Cancer
Helmut Bonkhoff et al.
PROSTATE (2010)
Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells
T. Terakawa et al.
BRITISH JOURNAL OF CANCER (2009)
Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival
Barbara Wegiel et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma
Peter M. Voorhees et al.
CLINICAL CANCER RESEARCH (2007)
Interleukin-6 and its receptor in cancer - Implications for translational therapeutics
David S. Hong et al.
CANCER (2007)
The NF-κB/IL-6 pathway in metastatic androgen-independent prostate cancer:: new therapeutic approaches?
Bernard Paule et al.
WORLD JOURNAL OF UROLOGY (2007)
Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression
Soo Ok Lee et al.
PROSTATE (2007)
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1
I. T. Cavarretta et al.
ONCOGENE (2007)
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: A minnie pearl cancer research network phase II trial
John D. Hainsworth et al.
CLINICAL GENITOURINARY CANCER (2007)
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer
Robert Dreicer et al.
CLINICAL CANCER RESEARCH (2007)
Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328
Hannes Steiner et al.
PROSTATE (2006)
Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity
Josep Domingo-Domenech et al.
CLINICAL CANCER RESEARCH (2006)
Mechanisms leading to the development of hormone-resistant prostate cancer
Susan Kasper et al.
UROLOGIC CLINICS OF NORTH AMERICA (2006)
Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice
L Wallner et al.
CANCER RESEARCH (2006)
Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells
T Gritsko et al.
CLINICAL CANCER RESEARCH (2006)
Mechanisms of the development of androgen independence in prostate cancer
A So et al.
WORLD JOURNAL OF UROLOGY (2005)
Androgen receptor signaling: Mechanism of interleukin-6 inhibition
L Jia et al.
CANCER RESEARCH (2004)
Preoperative chemotherapy increases cytokine production after lung cancer surgery
S Endo et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2004)
Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway
SO Lee et al.
PROSTATE (2004)
Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells
YS Pu et al.
PROSTATE (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer?
NM Corcoran et al.
BJU INTERNATIONAL (2003)
Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting
SY Sung et al.
DIFFERENTIATION (2002)
NF-κB in cancer:: From innocent bystander to major culprit
M Karin et al.
NATURE REVIEWS CANCER (2002)
Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways
T Ueda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Interleukin-6 is an autocrine growth factor in human prostate cancer
D Giri et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Interleukin-6-and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells
PD Deeble et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway
H Miyake et al.
ENDOCRINOLOGY (2000)
Share Paper
